These days, Regeneron (NASDAQ:REGN) seems to be the miracle stock that biotech investors are looking for. Sales of its biologic drug for ocular health, Eylea, and its anti-inflammatory drug, Dupixent, are soaring. Meanwhile, the company is also developing a promising antibody cocktail against COVID-19. In response, the market has pushed the shares up almost 60% year to date.
But I think the stock's momentum is not yet over, and now is an ideal time for investors who may have sat on the sidelines for too long to open a position. That's because of some crucial developments that may provide Regeneron's revenue and bottom line with another significant lift.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,